Завершено
Фаза II
Беларусь
ST-0529 · Sublimity Therapeutics (Hold Co) Ltd.
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis